Mohd Qamar, MD
Interventional Cardiology · Skokie, ILNPI 1568759272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,568 of the $23,041 with a category attached, or 71.9%. 34 manufacturers reported payments, led by Chiesi USA, Inc. at 57.5% of the total. 2025 is the largest year on record at $13,991, more than ten times the $112 reported in 2019.
Across 204 payments — averaging $112.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$13K
- Penumbra, Inc.$4K
- Inari Medical, Inc.$874
- Johnson & Johnson$732
- Novo Nordisk$484
- Pfizer$410
- plus $3K from 28 others
Across 244 payments — averaging $446.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Imperative Care, Inc$50K
- Novo Nordisk AS$32K
- Novartis$22K
- Siemens Medical Solutions USA, Inc.$5K
What the payments were for
- Speaking & faculty fees$16,56872%
- Travel & lodging$1981%
- Food & beverage$6,16627%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 7 | $13,244 |
| Penumbra, Inc. | 3 | $4,330 |
| Inari Medical, Inc. | 8 | $874 |
| Johnson & Johnson | 40 | $732 |
| Novo Nordisk | 15 | $484 |
| Pfizer | 15 | $410 |
| Boehringer Ingelheim | 13 | $403 |
| Amgen | 5 | $300 |
| Novartis | 14 | $293 |
| Medtronic | 11 | $252 |
| Philips North America LLC | 1 | $233 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $222 |
| Cardiovascular Systems Inc. | 12 | $218 |
| Opsens Inc. | 6 | $132 |
| Abiomed | 3 | $116 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Actelion Pharmaceuticals US, Inc. | 1 | $95 |
| Imperative Care, Inc | 4 | $86 |
| AstraZeneca | 5 | $72 |
| Boston Scientific | 3 | $68 |
| Abbott | 2 | $53 |
| Cordis US CORP. | 2 | $40 |
| Terumo Medical Corporation | 2 | $40 |
| Lemaitre Vascular, Inc. | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Bridgebio Pharma, Inc. | 1 | $27 |
| Bayer | 1 | $25 |
| Surmodics, Inc. | 2 | $23 |
| Stryker | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Teleflex LLC | 1 | $18 |
| Thrombolex, Inc. | 1 | $17 |
| Elutia, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KENGREAL$13,203
- Indigo System$4,330
- FLOWTRIEVER CATHETER, S$785
- CT THROMBECTOMY SYSTEM KIT$785
- US Und$233
- Repatha$122
How this compares
$23,041 in reported general payments places this provider in the 75th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 380 | $418,692 |
| XareltoRivaroxaban | 222 | $256,717 |
| JardianceEmpagliflozin | 65 | $69,329 |
| OzempicSemaglutide | 38 | $39,954 |
| BrilintaTicagrelor | 67 | $34,832 |
| FarxigaDapagliflozin Propanediol | 40 | $34,463 |
| EntrestoSacubitril/Valsartan | 27 | $27,480 |
| Repatha SureclickEvolocumab | 40 | $21,794 |
| Repatha SyringeEvolocumab | 13 | $13,008 |
| Rosuvastatin Calcium | 564 | $7,872 |
| MultaqDronedarone Hcl | 12 | $4,695 |
| Ezetimibe | 138 | $4,192 |
| Metoprolol Succinate | 340 | $4,002 |
| Prasugrel Hcl | 70 | $3,473 |
| Atorvastatin Calcium | 386 | $3,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $410 | $418,692380 claims |
| Johnson & JohnsonXarelto | $732 | $256,717222 claims |
| Boehringer IngelheimJardiance | $403 | $69,32965 claims |
| AstraZenecaBrilinta, Farxiga | $72 | $69,295107 claims |
| Novo NordiskOzempic | $484 | $39,95438 claims |
| NovartisEntresto | $293 | $27,48027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Skokie
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.